Clinical Trial Update: EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for EGEN-001 in persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Ovarian Carcinoma
• Peritoneal Carcinoma

Drugs mentioned

• EGEN-001

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-11-30